Opinion on Pharmaceuticals in Switzerland

Published within

« | 1 | 2 | 3 | » »|

Type Product title / description Pub Price
CommentWire
CommentWire

Novartis: Eastern European generics to bring multiple rewards

Buying Slovenia's Lek gives an East European footing to Novartis' already large generics business. Lower R&D costs there should allow Novartis to move into the higher value specialty generics segment. The acquisition also gives Novartis revenues from generic Augmentin, which, unlike its own version of the product, are not dogged by risk of litigation.

Published By Datamonitor
04 Sep 2002
CommentWire
CommentWire

Roche: synergies provide boost despite vitamin deficiency

Roche's acquisition of Disetronic looks set to boost its presence in the diabetes market. But its enthusiasm will be tempered by news that the spin-off of its vitamin business will reap lower rewards than expected, while further funds must be set aside to settle price rigging claims. Even so, Roche and Disetronic will enjoy some valuable synergies.

Published By Datamonitor
12 Feb 2003
CommentWire
CommentWire

Roche: cautious start to metabolic syndrome development

JTT-705, which Roche is to license from Japan Tobacco, is a novel anti-dyslipidemic that will further enhance the company's cardiovascular risk factor offering. This latest move could ultimately place Roche in a potentially advantageous position in the growing metabolic syndrome market, though it marks only the start of a long process to increase its currently meager offering in this field.

Published By Datamonitor
21 Oct 2004
CommentWire
CommentWire

Novartis: Glivec provides more impressive results

Patients with chronic myeloid leukemia (CML) receiving 800mg of Glivec are more likely to attain complete cytogenetic response compared to the standard dose of 400mg. If these preliminary results translate into improved survival for CML patients then this will undoubtedly secure further revenue for Novartis [NVS] as physicians switch to high dose Glivec.

Published By Datamonitor
07 Dec 2004
CommentWire
CommentWire

Genentech: Avastin may drive it into pole position

Positive trial data for Avastin drove Genentech's [DNA] share price up by almost 25% and parent company Roche's [ROCZ.S] share price by over 5%. Roche and Genentech have partnered to form the largest global player for cancer drugs, and Avastin looks set to provide them with another superstar product. Genentech's future as a major biotech player in the cancer market thus seems assured.

Published By Datamonitor
16 Mar 2005
CommentWire
CommentWire

Roche/GSK: monthly formulation puts Boniva in pole position

The green light for Boniva sees it join Merck & Co's [MRK] Fosamax and Aventis's [SNY] Actonel as the newest member of the bisphosphonate family - a class of drugs that treat osteoporosis by increasing bone mineral density. Adherence to bisphosphonate regimens can be difficult for many patients, but Boniva's monthly formulation offers a major advance in overcoming this issue.

Published By Datamonitor
30 Mar 2005
Expert View
Expert View

Novartis's novel bronchodilator paves way for potent COPD combinations

Novartis has unveiled promising Phase II data for its once-daily bronchodilator, indacaterol (QAB-149). With a long duration of action, rapid onset of action and clean side effects profile, the drug could provide a new standard for bronchodilator therapy in patients with asthma and chronic obstructive pulmonary disease (COPD).

Published By Datamonitor
09 Jun 2005
CommentWire
CommentWire

Roche: buying up for biotech boost

Roche has announced that it will acquire GlycArt for approximately E150 million, in a move that will boost the healthcare giant's position in the biologics, and particularly oncology, markets. The deal promises to strengthen Roche's drug development capabilities and help maintain the large increases in sales drawn from its therapeutic anti-cancer antibodies.

Published By Datamonitor
20 Jul 2005
Expert View
Expert View

Roche reinforces its HIV portfolio

Recently presented data has highlighted the efficacy of Roche and Trimeris' Fuzeon plus new antiretrovirals in treatment-experienced HIV patients. The data forms part of an ongoing program of studies into the use of Fuzeon with several pipeline drugs, including the novel CCR5 inhibitors, and underlines Roche's continued commitment to the HIV market. Datamonitor's Laura Harris reports...

Published By Datamonitor
02 Aug 2005
CommentWire
CommentWire

Novartis: premium price for Chiron still to come

Chiron has snubbed Novartis' offer to acquire the remaining shares of the company that it does not already own, calling the offer "inadequate". Chiron no doubt wants to hold out for a better offer, which is a wise move since, as Novartis will be the key benefactor from the takeover, the Swiss company is likely to significantly increase its bid.

Published By Datamonitor
07 Sep 2005

« | 1 | 2 | 3 | » »|

No help is available.